



More pharma patent litigations in store Ranbaxy, Dr. Reddy's prepare for long battlePosted AtThe Hindu Business Line PFIZER may have won a favourable ruling
from the UK court in its battle against the domestic
pharma major, Ranbaxy Laboratories, over its patent
for the anti-cholesterol drug, `Lipitor'. But officials
of Ranbaxy and Dr Reddy's Laboratories (DRL), which
lost a patent case in the US some time ago, maintain
that the losses incurred have not deterred them from
pursuing litigations in order to make the most of the
180-day market exclusivity in the case of a win. So,
even if Pfizer has been able to get the upper hand in
the UK litigation and Novartis having gained on its
anti-fungal drug Lamisil, Ranbaxy and DRL too have scored
with their successful challenge of GlaxoSmithKline (GSK)'s
and Eli Lilly's patent of `Ceftin' and `Prozac' respectively. October 18, 2005
|